When standard therapies for mCRPC are no longer effective, understanding the available international review pathways becomes critical.
China's pharmaceutical and hospital infrastructure for Actinium-225 PSMA radioligand therapy is expanding rapidly. However, macroscopic manufacturing capacity does not equal automatic patient access. Navigating the complex nuclear medicine protocols, specialized isolation wards, and S2 medical visa requirements requires precise administrative expertise.
In our latest guide, we break down the administrative realities of Medical Tourism China for advanced oncology patients. As a professional medical concierge provider, MedBridgeNZ Limited does not provide medical advice or treatment. Instead, we coordinate the complex logistics—from clinical record translation to hospital liaison services—ensuring your case is properly formatted for multidisciplinary review by licensed Chinese institutions.
Discover the step-by-step administrative pathway and pre-review record checklist here: Actinium-225 PSMA Access in China for mCRPC: What International Patients Should Know
